175 results on '"Maurel, J."'
Search Results
2. Targeted transcriptomic analysis of pancreatic adenocarcinoma in EUS-FNA samples by NanoString technology
3. 763P Combined gene signature (T-cell inflamed gene expression profile – TcellinfGEP – & IMMETCOLS) identifies a metabolic rewiring program, key for immune evasion
4. 383P An exosome-based liquid biopsy assay for predicting therapeutic outcomes in patients with metastatic colorectal cancer treated with anti-EGFR therapy: Results from prospective, first-line, PULSE and POSIBA trials
5. 433P Pre-treatment and post-treatment MRI extramural venous invasion, predicts disease-free survival and overall survival, in locally advanced rectal cancer
6. 352P Mutations of SMAD4 and FBXW7 predict poor outcome in TP53-driven metastatic colorectal cancer
7. 338P A new clinically applicable immune-metabolic signature (IMMETCOLS) reveals metabolic singularities in consensus molecular subtypes (CMS) in colorectal cancer
8. DEDICATED DIGITAL MRNA DETECTION METHOD WITH EUS FNA SAMPLES FOR STABLISHING PANCREATIC ADENOCARCINOMA (PDAC) GENE EXPRESSION PROFILE SIGNATURE
9. Impact of Microscopic Incomplete Resection for Colorectal Liver Metastases on Surgical Margin Recurrence: R1-Contact vs. R1≪1mm Margin Width
10. 416P Randomized phase II trial of second-line FOLFIRI-panitumumab vs FOLFIRI alone in Ras wild type (wt) metastatic colorectal cancer (mCRC) patients beyond progression to first-line FOLFOX-panitumumab: BEYOND study (GEMCAD 17-01)
11. 442P A phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. GEMCAD 16-02 (AVEVAC trial)
12. 996P An immune-metabolic signature correlates with immune-suppressive patterns and with outcome, across tumor types
13. 81P Baseline circulating CD4+PD1+high T cells (TCD4PD1H) as predictors of survival in patients (P) with solid tumors treated with immune-checkpoint inhibitors (ICI)
14. P-228 Phase II multicentric randomized controlled trial to compare first-line treatment with FOLFOX6m + mAB alone or in combination with liver chemoembolization (Lifepearls-Irinotecan) in poor prognosis colorectal cancer with liver-limited disease
15. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
16. AN ANALYTIC FORMULATION OF ELECTRON DISTRIBUTION FUNCTION FROM TRANSPORT COEFFICIENTS OF ELECTRON SWARM
17. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)
18. 548P Molecular pre-screening using comprehensive gene panels offered by clinical trials (CT)
19. 474P Prognostic and predictive role of Consensus Molecular Subtypes (CMS) determined by immunohistochemistry in metastatic colorectal cancer (mCRC)
20. 471P Identification and validation of a new prognostic score in metastatic colorectal cancer (mCRC): GEMCAD score
21. 109P Subpopulations of peripheral blood lymphocytes and response to immunotherapy across cancer-types
22. 476P Mutational profiling allows the stratification of metastatic colorectal cancer patients with poor prognosis
23. 427P Value of magnetic resonance diffusion weighted imaging in the identification of complete responder patients with rectal cancer treated with neoadjuvant therapy
24. Cellulite pelvienne sur bartholinite à streptocoque pyogènes : à propos d’un cas
25. Virtual colonoscopy
26. Mutational profile of non-metastatic anal squamous cell carcinoma: a restrictive high impact genetic variants analysis
27. Immune signatures identify three immune clusters in mCRC, with potential clinical implications
28. Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study
29. Whole-exome sequencing of non-metastatic anal squamous cell carcinoma: a prognostic genetic variants analysis
30. Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND)
31. Do we need adjuvant therapy in patients with rectal cancer and pathologic complete response, after conventional preoperative chemoradiation and laparoscopic (LapTME) or Transanal total mesorectal excision (TaTME)?
32. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
33. Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM)
34. Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy: Combined analysis of two prospective clinical trials
35. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
36. Prospective biomarker study in advanced RAS wild-type colorectal cancer: POSIBA trial
37. AVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)
38. Lithium as a disease-modifying agent for prion diseases
39. YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD)
40. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS)
41. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial
42. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial
43. SEOM Clinical Guideline for the treatment of pancreatic cancer (2016)
44. LA ASCITIS DETECTADA POR USE PREDICE LA EXISTENCIA DE CARCINOMATOSIS PERITONEAL EN LOS PACIENTES CON ADENOCARCINOMA DE PÁNCREAS
45. Prospective evaluation of BRAF, PI3K and PTEN as predictive and prognostic biomarkers in first-line advanced KRAS wild-type colorectal cancer treated with FOLFOX or FOLFIRI plus bi-weekly cetuximab. GEMCAD 10-02
46. Neutrophil-to-lymphocyte ratio as a biomarker for prognosis in localized colorectal carcinoma
47. PULSE, a phase 2 study of mFOLFOX6-panitumumab (P) with biomarker stratification as first-line chemotherapy (CT), in patients (pts) with KRAS (exon 2) metastatic colorectal cancer (mCRC). A GEMCAD 09-03 study
48. Biliary tract cancers: SEOM clinical guidelines
49. 2161 The prognostic significance of radiologic and pathologic factors after neoadyuvant chemotherapy for T3 rectal cancer (RC): 3-years update GEMCAD 0801 trial
50. 2250 Phase II trial of neoadjuvant gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy in resectable pancreatic adenocarcinoma. A GEMCAD 10–03 trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.